Title:LncRNA SBF2-AS1: A Budding Star in Various Cancers
Volume: 28
Issue: 18
Author(s): Fangshun Tan, Jinlan Chen, Bei Wang, Zhuoying Du, Jie Mou, Yinxin Wu, Yuling Liu, Fangnan Zhao and Chengfu Yuan*
Affiliation:
- Third-Grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine,
China Three Gorges University, Yichang 443002, China
- Medical College, China Three Gorges University, Yichang 443002,
China
Keywords:
Lnc RNA, SBF2-AS1, cancer, biomarker, target, diagnosis, prognosis, hepatocellular carcinoma, metastasis, angiogenesis.
Abstract: Long non-coding RNA (lncRNA) is a new kind of RNA with a length of over 200 nucleotides. Current
frontiers revealed that lncRNAs implicate in various tumor progression, including tumorigenesis, proliferation,
migration, invasion, metastasis, and angiogenesis. Recently discovered long non-coding RNA SETbinding
factor 2 antisense RNA 1 (lncRNA SBF2-AS1), an oncogenic antisense RNA to SBF2, locates at
11p15.1 locus and is 2708 nt long. Accumulating evidence has demonstrated that lncRNA SBF2-AS1 participates
in the progression of the various tumor, including pathogenesis, diagnosis, treatment, and prognosis of
acute myeloid leukemia (AML), breast cancer (BC), cervical cancer (CC), clear cell renal cell carcinoma
(ccRCC), colorectal cancer (CRC), diffuse large B-cell lymphoma (DLBCL), esophageal squamous cell carcinoma
(ESCC), gastric cancer (GC), glioma, glioblastoma (GBM), hepatocellular carcinoma (HCC), lung cancer
(LC), lung adenocarcinoma (LUAD), non-small cell lung cancer (NSCLC), osteosarcoma (OS), pancreatic cancer
(PC), papillary thyroid cancer (PTC), small cell lung cancer (SCLC). Therefore, we summarized the underlying
mechanisms of lncRNA SBF2-AS1 in various cancers to utilize its therapeutic function in target-selective
treatment modalities.